NASDAQ$PTGX
Protagonist Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Protagonist Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024.
Protagonist Therapeutics reported a significant increase in revenue and net income for Q4 2024, driven by a $165.0 million icotrokinra milestone payment. The company also announced positive topline results for its Phase 3 ICONIC-LEAD and ICONIC-TOTAL studies for icotrokinra and is anticipating key clinical trial results for rusfertide and icotrokinra in March 2025.
- Protagonist earned a $165.0 million icotrokinra milestone in Q4 2024, received in January 2025.
- PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide, was nominated as a development candidate in Q4 2024.
- Topline results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera are expected in March 2025.
- Topline results for icotrokinra Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis are expected in March 2025.
Headline financials
Revenue & EPS history
Protagonist · Revenue · Quarterly
$171M
Forward guidance
Protagonist Therapeutics anticipates several key milestones in the near future, including clinical trial readouts and new development candidate nominations, supported by a strong cash position.
Tailwinds
- Topline results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in March 2025.
- Topline results for icotrokinra Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in March 2025.
- Anticipated progression of oral IL-17 peptide antagonist PN-881 into clinical studies.
- Expectation to nominate new development candidates from oral obesity and oral hepcidin programs in 2025.
- Strong cash position of $559.2 million as of December 31, 2024, combined with $165.0 million milestone payment, anticipated to provide cash runway through at least end of 2028.
Headwinds
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+3.2%
Avg return
Earnings day
+5.4%
Avg return
5 days after
+8.3%
Avg return
30 days after
51%
20 / 39 earnings
Positive
+75.1%
Q1 2020
Best reaction
-21.2%
Q1 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | -0.2% | +3.3% | |
| Q4 2025 | -0.3% | +7.8% | +13.3% | |
| Q3 2025 | -0.2% | +6.4% | +12.4% | |
| Q1 2025 | +2.4% | +3.2% | +22.9% | |
| Q4 2024 | -7.1% | -6.2% | +35.6% | |
| Q3 2024 | -2.9% | -9.3% | -11.6% | |
| Q2 2024 | +0.0% | +8.2% | +17.4% | |
| Q1 2024 | +4.0% | +8.3% | +30.5% | |
| Q4 2023 | +3.0% | +8.9% | -2.0% | |
| Q3 2023 | +10.2% | +9.0% | +22.8% | |
| Q2 2023 | +3.3% | -2.0% | +5.2% | |
| Q1 2023 | +1.5% | +3.3% | +15.3% | |
| Q4 2022 | -8.4% | -9.9% | -25.9% | |
| Q3 2022 | -0.5% | +9.4% | +0.4% | |
| Q2 2022 | +2.2% | -1.6% | -21.1% | |
| Q1 2022 | -0.3% | -10.3% | -6.4% | |
| Q4 2021 | +7.2% | -0.7% | -2.3% | |
| Q3 2021 | +5.0% | +7.4% | +0.1% | |
| Q2 2021 | -2.2% | -0.4% | -0.8% | |
| Q1 2021 | -0.4% | -0.1% | +19.3% | |
| Q4 2020 | +3.5% | +2.8% | -11.4% | |
| Q3 2020 | +14.2% | +6.6% | +11.0% | |
| Q2 2020 | +8.3% | +2.3% | +23.8% | |
| Q1 2020 | +75.1% | +97.4% | +98.0% | |
| Q4 2019 | -4.8% | +5.1% | -7.6% | |
| Q3 2019 | -19.3% | -14.2% | -37.5% | |
| Q2 2019 | +0.8% | -2.9% | +60.6% | |
| Q1 2019 | +20.8% | +16.3% | +31.4% | |
| Q4 2018 | +0.1% | +22.3% | +22.2% | |
| Q3 2018 | +14.1% | +22.3% | -14.6% | |
| Q2 2018 | -1.8% | -6.4% | -18.1% | |
| Q1 2018 | -21.2% | -22.4% | -13.5% | |
| Q4 2017 | -2.0% | +1.4% | -57.5% | |
| Q3 2017 | +8.9% | +16.2% | +25.2% | |
| Q2 2017 | -7.7% | -4.4% | +33.6% | |
| Q1 2017 | +10.5% | +14.3% | +21.1% | |
| Q4 2016 | -0.6% | +0.4% | -16.8% | |
| Q3 2016 | -1.6% | +3.4% | -16.5% | |
| Q2 2016 | +9.4% | +19.1% | +63.8% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro